Trials / Completed
CompletedNCT03413644
Evaluation of ClearLLab Leukemia and Lymphoma Panels
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 482 (actual)
- Sponsor
- Beckman Coulter, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Multi-center study of specimens from subjects presenting to the flow cytometry laboratory as part of their standard of care for hematological diseases work-up.
Detailed description
Multi-center study of specimens from subjects presenting for flow cytometry immunophenotyping as part of their standard of care for hematological diseases work-up. Residual specimens will be tested using the ClearLLab Panels to determine the presence or absence of an abnormal phenotype and compare results to clinical impression (hematological malignancy or non-malignancy).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Flow Cytometry | Immunophenotyping of residual clinical samples tested with ClearLLab diagnostic reagent on a specified Flow Cytometer |
Timeline
- Start date
- 2017-11-14
- Primary completion
- 2018-04-27
- Completion
- 2018-04-27
- First posted
- 2018-01-29
- Last updated
- 2018-07-13
Locations
4 sites across 3 countries: United States, Canada, Germany
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03413644. Inclusion in this directory is not an endorsement.